Absstract of: GB2580006A

A method of decontaminating air from lipophilic airborne contaminants (e.g. lipid enveloped virus) comprising delivering soap bubbles into the air, wherein the soap bubbles comprise a solvent and a surfactant. Preferably the surfactant is sodium laureth sulphate and/or sodium lauryl sulphate. The soap bubbles may further comprise an evaporation suppressant such as glycerol, polyethylene glycol and/or corn syrup. In one embodiment the lipophilic airborne contaminants are lipid-coated viruses, such as coronaviruses like COVID-19. The method can be computer-implemented and comprises a decontamination signal transmitter which transmits a wired or wireless decontamination activation signal to the air decontamination apparatus, which in response, produces and delivers soap bubbles into the air. There may optionally be a decontamination deactivation signal which ceases production of the soap bubbles.

Absstract of: EP3670669A1

The invention is directed to a method for the detection of SARS-CoV-2 in a plurality of biological samples of living beings and to a kit for carrying out said method.

Absstract of: WO2020114444A1

Pharmaceutical use of diacerein. Experiments show that diacerein can effectively inhibit hepadnavirus, retrovirus, enterovirus, orthomyxovirus, filovirus, reovirus, arenavirus, hepatitis E virus, astrovirus, orbivirus, coronavirus, parvovirus, adenovirus, polyomavirus, herpes virus, poxvirus, human papilloma virus, paramyxovirus, flavivirus, alphavirus, and rhabdovirus.

Absstract of: US2020179367A1

In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.

Absstract of: RU2723008C1

FIELD: biotechnology.SUBSTANCE: The invention relates to the field of biotechnology. Created are a genetic construct for the expression of recombinant SARS-CoV-2 virus protein RBD, a strain of Chinese hamster ovary cells CHO-S-RBD that produces a recombinant protein - a receptor-binding domain (RBD) of SARS-CoV-2 virus, which can be used for diagnostic purposes. Described is a method for producing a strain of Chinese hamster ovary cells CHO-S-RBD being a producer of recombinant SARS-CoV-2 virus protein RBD, containing a genetic construct comprising SEQ ID NO: 1; introducing the specified genetic constructs into cells by lipofection; selecting cells on Hygromycin B antibiotic. Created is a strain of Chinese hamster ovary cells CHO-S-RBD, a producer of recombinant SARS-CoV-2 virus protein RBD. Developed is a method for producing recombinant SARS-CoV-2 virus protein RBD, comprising: culturing a strain of Chinese hamster ovary cells CHO-S-RBD; purifying chromatographically the recombinant SARS-CoV-2 virus protein RBD from culture medium of the Chinese hamster ovary strain CHO-S-RBD; confirming the production of recombinant SARS-CoV-2 protein RBD. Created is a recombinant SARS-CoV-2 virus protein RBD to detect antibodies to SARS-CoV-2. Created is a test system for enzyme immunoassay of human serum or plasma. Developed is a method for analyzing serum or plasma of COVID-19 convalescents to sample the most promising ones for treating patients infected with SARS-CoV-2. Developed is a

Absstract of: AU2020100641A4

Abstract The present invention describes compositions comprising azithromycin, vitamin C, zinc and acetylsalicylic acid (Aspirin) for the treatment of fever; cough; diarrhoea and flu like symptoms.

Absstract of: WO2020105873A1

The present invention relates to a method for obtaining a whole genome sequence for determining the presence of infection by coronavirus, and a use thereof. A method, a kit and a composition of the present invention comprise a set of 11 universal primers capable of amplifying the genomic sequence of coronavirus, thereby enabling easy and rapid identification of the presence of a target virus in a sample and related diseases. In addition, through whole genome sequencing, mutations of novel coronavirus can be identified so as to be effectively used in the identification of novel viruses.

Absstract of: US2020164058A1

An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.

Absstract of: AU2020100545A4

Abstract An innovative ethyl alcohol, chlorite, hydrogen peroxide, tea tree oil extract (Melaleuca alternifolia) based anti- SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) viral surface sanitizer comprising of a mixture of biocidal agents: (a) Ethyl alcohol (contains an ethyl group [saturated two carbon moiety] is an alkyl substituent derived from ethane (C 2H)) comprising of 65-70 % w/w of the composition; (b) Sodium and/or Calcium Hypochlorite [Na(CIO)/Ca(CIO) 2 ] comprising of 0.1% w/w of the composition; (c) 0.5% hydrogen peroxide comprising of 0.1% w/w of the composition (d) 0.01% Tea Tree Oil Extract (Melaleuca alternifolia) w/w of the composition.

Absstract of: AU2020100564A4

A method of solving problems on the coronavirus impact on the world economy by forecasting and controlling the spread of the virus.

Absstract of: RU2720614C1

FIELD: biotechnology, immunology, virology.SUBSTANCE: The invention relates to the field of biotechnology, immunology and virology, in particular to an immunobiological agent for the prevention of diseases caused by the severe respiratory syndrome virus SARS-CoV-2. Also, a method is disclosed for inducing specific immunity to the SARS-CoV-2 virus, comprising administering one or more immunobiological agents to the mammalian body for the prevention of diseases caused by the severe respiratory syndrome virus SARS-CoV-2. The invention allows to effectively induce an immune response against SARS-CoV-2 virus.EFFECT: the invention allows to effectively induce an immune response against SARS-CoV-2 virus.10 cl, 5 dwg, 12 tbl, 15 ex

Absstract of: RU2720713C1

FIELD: medicine; biology.SUBSTANCE: invention refers to medicine and biology, namely to detection of SARS-CoV-2 coronavirus RNA in samples of biological material of human and animals, as well as in samples of environmental objects. Described is a set of synthetic oligonucleotides for detecting of SARS-CoV-2 coronavirus RNA includes a pair of primers selected from: 5'-GGTAAGAGTCATTTTGCTATTGGCC-3' and 5'-CTTGTAAAGTTGCCACATTCCTACG-3'; 5'-GTAAGAGTCATTTTGCTATTGGCC-3' and 5'-TTGTAAAGTTGCCACATTCCTACG-3'; 5'-TAAGAGTCATTTTGCTATTGGCC-3' and 5'-TGTAAAGTTGCCACATTCCTACG-3'; 5'-AAGAGTCATTTTGCTATTGGCC-3' and 5'-GTAAAGTTGCCACATTCCTACG-3'; 5'-AGAGTCATTTTGCTATTGGCC-3' and 5'-TAAAGTTGCCACATTCCTACG-3'; 5'-TGAGTGAAATGGTCATGTGTGG-3' and 5'-AGACCTTGAGATGCATAAGTGC-3'. From a pair of selected primers, one oligonucleotide can have a fluorescent label. A set of synthetic oligonucleotides for detecting of SARS-CoV-2 coronavirus RNA can additionally contain a fluorescent labeled oligonucleotide probe complementary or partially complementary to a nucleotide sequence flanked by a selected pair of primers.EFFECT: technical result of the invention consists in providing universal information value of detecting of SARS-CoV-2 RNA based on RT-PCR by eliminating the risk of obtaining false-negative results of RT-PCR in the presence of mutations in the amplified region of the SARS-CoV-2 genome.3 cl, 7 ex

Absstract of: KR102109196B1

본 발명은 2019 신종코로나바이러스(2019 novel Coronavirus) 검출용 LAMP(Loop-mediated isothermal amplification)용 조성물 및 이의 용도에 관한 것으로, 본 발명의 LAMP 조성물을 이용한 2019 신종코로나바이러스의 검출 방법은 시료로부터 별도의 핵산 추출 및 정제 과정 없이도 간단한 실시간 등온증폭기기만으로 분자진단 검사 결과를 현장에서 1시간 이내에 확인할 수 있으므로, 현장진단검사 등에 유용하게 활용될 수 있을 것이다.

Absstract of: AU2020100453A4

Decontamination Dispersal Aerosol Unit for indoor hands-free use, said unit will come in range of sizes suitable for public and private transportation, office spaces, and private homes. The unit will deploy an aerosol variant of the disinfectant, covering all exposed areas (within specified coverage capabilities). This product will mitigate existing risks (e.g. viruses such as COVID-19) within essential services and industries allowing best opportunity for business as usual functions.

Absstract of: WO2020080682A1

The present invention relates to a novel quinolinone derivative, a preparation method therefor, and an antiviral composition containing same as an active ingredient. A novel quinolinone derivative provided in one aspect of the present invention exhibits an excellent inhibitory activity against a coronavirus infection, and thus can be effectively used as a pharmaceutical composition for preventing or treating a disease caused by a coronavirus infection, that is, MERS.

Absstract of: AU2020100400A4

PROPOSED THERAPY TO REDUCE EFFECTS OF VIRAL INFECTIONS The disclosed proposed therapy to reduce effects of viral infections is a combination of lifestyle changes, vitamin supplements and prescription medicines that will reduce the impact of viral infections by boosting the body's immune system. The outcomes of adopting and implementing these strategies will amaze both young an older people. For example, younger people may only have to implement the lifestyle changes to have an extremely healthy outcome.

Absstract of: US2020123205A1

The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCRαβ-CD3δε-CD3γε-ζζ signaling complex. Yet more specifically, the peptides act on the TCRα/CD3δε/ζζ signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions. Specifically, the compositions are useful in the treatment and/or prevention of a disease or condition where T cells are involved or recruited. The compositions of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

Absstract of: CN110951756A

The invention discloses nucleotide acid sequences expressing SARS-CoV-2 virus antigen peptide and application of the nucleotide acid sequences. The nucleotide acid sequence comprise SEQ ID NO:1, SEQ ID NO:2 or a sequence with at least 90% homology. Nucleotide acid sequences in embodiments can be effectively expressed in human cells to produce corresponding polypeptides and produce corresponding immune protection reactions by induction, and are expected to be developed into SARS-CoV-2 vaccines.

Absstract of: KR20200032050A

The present invention relates to a diagram with respect to a triple knockout DNA antisense oligomer for coronavirus epidemic originated from Wuhan, China. The virus based on Wuhan pneumonia virus sequencing which has already progressed on January 13 is investigated, and a prescription is included. A single strand patent was secured in 2012. A liposome transports a single strand DNA for intracellular procurement and is coupled to three parts to remove virus genome.

Absstract of: CN110894217A

The invention relates to the technical field of immunodetection, and discloses a bovine coronavirus chimeric antigen and an aurosol immunochromatographic assay test strip for detecting a bovine coronavirus antibody. The sequence of the chimeric antigen is shown as SEQID NO:1. The invention provides a novel bovine coronavirus chimeric antigen. When being used as a detection antigen of the bovine coronavirus antibody, the bovine coronavirus chimeric antigen has high specificity, repeatability and accuracy, and can be applied to associated immunochromatographic assay detection products. The results are visual and can be judged through naked eyes, the bovine coronavirus antibody in serum can be quickly and specially detected, and the problem for quick rapid diagnosis of diarrhoea of calves ina scaleable milk cow farm is solved. The bovine coronavirus chimeric antigen has high use value, and grass-roots unit promotion and application are facilitated.

Absstract of: CN110870402A

The invention relates to traditional Chinese medicine compositions, and specifically discloses a prescription capable of treating pneumonia caused by 2019-nCoV (a novel coronavirus) infection as wellas application thereof. The prescription capable of treating the pneumonia caused by the 2019-nCoV infection comprises the following traditional Chinese medicine materials as raw materials in parts byweight: 9 parts of ephedra, 6 parts of roasted liquorice roots, 9 parts of apricot kernels, 15-30 parts of raw gypsum, 9 parts of cassia twigs, 9 parts of oriental waterplantain rhizome, 9 parts of zhuling, 9 parts of white atractylodes rhizomes, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of baical skullcap roots, 9 parts of ginger processed pinellia tubers, 9 parts of fresh ginger, 9 parts of aster, 9 parts of common coltsfoot flowers, 9 parts of blackberry lily rhizome, 6 parts of manchurian wildginger, 12 parts of Chinese yams, 6 parts of immature orange fruits, 6 parts of dried orange peel, and 9 parts of wrinkled gianthyssop herb. In combination with symptom manifestation of the pneumonia caused by the 2019-nCoV infection, the invention adopts an optimized and integrated traditional Chinese medicine prescription, thereby achieving synergistic treatment effects. According to current treatment results of diagnosed patients of different ages in many provinces and regions, the prescription capable of treating the pneumonia caused by the 2019-nCoV infection has true

Absstract of: KR20200023034A

The present invention relates to: an isoxazole derivative compound of chemical formula 1, useful as a substance for treating s respiratory viral infection disease coronavirus, in particular, Middle East respiratory syndrome coronavirus (MERS-CoV); a pharmaceutically acceptable derivative thereof; a manufacturing method thereof; and a pharmaceutical composition for treating coronavirus infection, which contains the compound as an active component.

Absstract of: KR20200020411A

The present invention relates to a monoclonal antibody which specifically recognizes spike protein of Middle East respiratory syndrome coronavirus (MERS-CoV) or a portion of the protein; or a functional fragment thereof. The monoclonal antibody or the functional fragment thereof includes one polypeptide sequence selected from a group consisting of the below polypeptide sequence. The monoclonal antibody comprises: a heavy chain including CDR1 region described as sequence number 1, CDR2 region described as sequence number 2, and CDR3 region described as sequence number 3; and a light chain including CDR1 region described as sequence number 4, CDR2 region described as sequence number 5, and CDR3 area described as sequence number 6. Therefore, the monoclonal antibody of the present invention can be applied to the diagnosis and treatment for the infection caused by MERS-CoV.

Absstract of: WO2020036403A1

The present invention relates to a monoclonal antibody capable of specifically recognizing a spike protein of Middle East respiratory syndrome coronavirus (MERS-CoV) or a portion of the protein, or a functional fragment of the monoclonal antibody; and to a use of same, wherein the monoclonal antibody or a functional fragment thereof is characterized by comprising any one polypeptide sequence selected from the group consisting of the following polypeptide sequences, and wherein the monoclonal antibody consists of a heavy chain comprising a CDR1 region represented by SEQ ID NO: 1, a CDR2 region represented by SEQ ID NO: 2, and a CDR3 region represented by SEQ ID NO: 3, and a light chain comprising a CDR1 region represented by SEQ ID NO: 4, a CDR2 region represented by SEQ ID NO: 5, and a CDR3 region represented by SEQ ID NO: 6.